Genetic testing provides valuable diagnostic and prognostic information about disease risk factors and carrier status that are often important in patient management decisions.
MPLN offers a complement of three molecular testing options to support all clinically relevant indications for CFTR testing including genotyping and patient stratification for clinical trial enrollment; FDA-cleared and approved for use by the New York State Department of Health (NYSDOH Clinical Laboratory Permit #8046).
The illumina Cystic Fibrosis 139 Variant expanded, pan-ethnic panel will detect most mutations targeted by the CFTR potentiator KALYDECO® (Ivacaftor).
Medical Genetics Tests
Abc-Z Molecular Diagnostic Oncology Tests
Cystic Fibrosis Luminex x-TAG 39 Variant Assay
Cystic Fibrosis MiSeqDx 139-Variant Assay by Next Generation Sequencing
Cystic Fibrosis MiSeqDx Clinical Sequencing Assay by Next Generation Sequencing